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ABSTRACT
Objectives: To implement an electronic laboratory utiliza-
tion management system (laboratory expert system [LES])
to provide safe and effective reductions in unnecessary clin-
ical laboratory testing.
Methods: The LES is a set of frequency filter subroutines
within the Veterans Affairs hospital and laboratory informa-
tion system that was formulated by an interdisciplinary med-
ical team.
Results: Since implementing the LES, total test volume has
decreased by a mean of 11.18% per year compared with our
pre-LES test volume. This change was not attributable to
fluctuations in outpatient visits or inpatient days of care.
Laboratory cost savings were estimated at $151,184 and
$163,751 for 2012 and 2013, respectively. A significant por-
tion of these cost savings was attributable to reductions in
high-volume, large panel testing. No adverse effects on pa-
tient care were reported, and mean length of stay for pa-
tients remained unchanged.
Conclusions: Electronic laboratory utilization systems can
effectively reduce unnecessary laboratory testing without
compromising patient care.
Health care expenditures in the United States continue
to rise at an alarming rate. They are projected to reach $4.4
trillion by 2018 (20.3% of projected gross domestic prod-
uct).1 Such an unsustainable rise presents many risks for the
future of the nation’s health care system as well as its econ-
omy. Laboratory testing is one factor that contributes to ris-
ing health care expenditures.2 It is estimated that laboratory
and pathology testing accounts for 4% of all yearly health
care costs.3 From 2005 to 2010, Medicare spending on all
part B laboratory services increased by 29%.4 This increase
was significantly disproportionate to the 10% increase in en-
rollment in Medicare part B.4 It is becoming increasingly
evident that cost stabilization and reduction, including
within-laboratory services, are necessary to place our na-
tion’s health care system back on a sustainable course.
Depending on the country, clinical setting, method, and
specific tests evaluated, studies have shown that a relatively
large percentage (up to 42%) of laboratory testing can be con-
sidered wasteful.5-8 Moreover, commonly ordered tests or test
panels are often cited as being overused.8 Redundant testing
alone has been estimated to waste up to $5 billion annually in
the United States.9 Redundant testing can occur when tests are
ordered by multiple clinicians treating a given patient, when
recurring orders are placed on a given patient (eg, daily CBC)
without recurring assessment of clinical necessity, when orders
are repeated at short time intervals that are unlikely to detect a
clinically relevant change, or when large panel testing is re-
peated to address a disturbance of one or a few analytes.
Laboratory utilization management systems are one
method that can effectively curtail a significant amount of
these unnecessary tests. Furthermore, utilization management
can also help to reduce many often overlooked consequences
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of inappropriate testing. For example, false-positive testing
can result in other inappropriate laboratory or defensive diag-
nostic testing. In addition, individuals without health insurance
may have to bear the financial impact of unnecessary testing.
For inpatients, a high frequency of blood draws can be disrup-
tive and lead to interruption of normal sleep patterns. In ex-
treme cases, repetitive blood draws can lead to hospital-
acquired anemia.7 Moreover, unnecessary testing can act to di-
vert nursing and phlebotomy staff from their performance of
other important tasks. In contrast, the potential exists for pa-
tient harm if utilization management is carried out with only
cost reduction as an end point. Therefore, utilization rules are
best targeted at tests that are demonstrably overused or ones
for which evidence-based guidelines exist. Ideally, hospital-
based clinical peer committees should establish specific test
utilization rules that are tailored to meet the demands of their
respective institutions.10,11
A variety of different laboratory utilization systems
have been proposed.2,10,12 Success in reducing redundant or
unnecessary laboratory testing has been demonstrated by
passive noninterruptive alerts that provide decision-making
support for physicians.12 This can include providing infor-
mation on test costs, previous test results, test information,
or ordering advice.12 Interruptive alerts that require an ac-
tion by the physician (eg, closing a pop-up alert) can also be
used.12 Finally, a more restrictive approach has been
described and effectively used.10 Test ordering frequency
filters for up to 44 tests were introduced following consult-
ation with clinical staff and resulted in an overall reduction
of 0.56% of total test volume and a reduction in laboratory
costs of 0.33%.10 Regardless of the method used for labora-
tory utilization, the end goal in all settings is to minimize
unnecessary laboratory expenditures without having an ad-
verse effect on patient outcomes.
Given the sheer bulk and complexity of testing services
offered at the typical clinical laboratory, the control of un-
necessary laboratory testing is best accomplished at the time
of order entry. This is facilitated by the widespread use of
computerized physician order entry (CPOE) systems that
allow for system-defined rules for utilization manage-
ment.12 Indeed, while many laboratory information systems
allow for the adoption of utilization management rules, the
implementation of testing rules in hospitals without CPOE
systems is largely ineffective, as they fail to provide deci-
sion support to the ordering physician.12 CPOE systems
have been shown to introduce significant quality improve-
ments to patient care, particularly in the reduction of med-
ical errors (reviewed in Cutler et al13).
The implementation of a robust and effective laboratory
utilization system can be a challenging undertaking for any
institution. It requires a significant amount of work and
communication from administrators, clinicians, laboratory
personnel, and information technology personnel. How the
utilization software will be designed and integrated into
existing ordering systems must be determined. Rules for test
appropriateness must be established based on a daunting
amount of information (eg, empiric or research-based evi-
dence, national guidelines, clinician and laboratory director
input, administrative input, cost reduction potential). The
tests that will be regulated must also be decided depending
on the specific needs and overarching goals of the institu-
tion. Despite all of these challenges, it is an undertaking that
can positively affect laboratory expenditures and help pro-
viders use laboratory testing more efficiently and effect-
ively. In this article, we describe our experience with a
laboratory utilization management system (Laboratory
Expert System) at the Richard L. Roudebush VA Medical
Center.
Materials and Methods
Clinical Setting
The Veterans Health Administration (VHA) is the gov-
ernment branch of the United States that is responsible for
the medical care of the nation’s veterans and dependents.
The VHA operates the largest health care system in the
United States, operating a nationwide network of 151
Medical Centers, 300 Veterans Centers, 820 Community-
Based Outpatient Clinics (CBOCs), and 135 nursing homes
that provide care to more than 8 million veterans. The
Richard L. Roudebush VA Medical Center, located in
Indianapolis, Indiana, provides acute inpatient medical, sur-
gical, psychiatric, neurologic, and rehabilitation care, as
well as both primary and specialized outpatient services for
approximately 60,000 veterans per year. It also serves as a
tertiary referral center for other Veterans Affairs (VA)
facilities in Indiana and Illinois, with 613,000 outpatient vis-
its and almost 7,900 inpatient episodes of care per year. The
150-bed medical center also serves as a teaching hospital
for the Indiana University School of Medicine.
Laboratory Expert System
The laboratory expert system (LES) is a set of subrou-
tines that have been incorporated into the VA hospital and
laboratory information system (also known as VistA:
Veterans Health Information Systems and Technology
Architecture). VistA is an integrated set of software applica-
tions that allow coordination between the electronic health
record, known as the Computerized Patient Record System
(CPRS), computerized order entry, electronic pharmacy pre-
scribing, and clinical guidelines. The LES is a gatekeeper
software system that allows the laboratory to suppress
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redundant testing by defining order frequency rules for spe-
cific tests or test panels for any given patient. At the time of
order entry into CPRS, a request for a specific laboratory
test or panel will be declined if the order exceeds the prede-
fined rule for order frequency. Rules can be turned off for
specific patient populations by test ordering site (eg,
emergency department and intensive care units). Clinicians
were also initially allowed to request that LES rules be
turned off for a specific patient for a defined period of time.
Finally, the ordering clinician could still obtain testing by
contacting the laboratory and asking for an exception for an
individual patient. Clinicians could not turn off the fre-
quency filter directly through CPRS; this functionality is
only available to the laboratory. A similar approach using a
much smaller number of tests was reported by a hospital fa-
cility in the Netherlands.10
System Implementation, Monitoring, and Revision
In the spring of 2011, the clinical laboratory was tasked
with reducing its annual budget of $7.5 million by $2 mil-
lion. In response to a solicitation for budget reduction ideas,
the Syracuse VA Medical Center (Syracuse, NY) suggested
the implementation of its LES laboratory utilization man-
agement system. As initially obtained from the Syracuse
VA Medical Center in July 2011, the LES consisted of a set
of subroutines that could be written into VistA and sup-
ported frequency filter rules for 12 tests. In September 2011,
the LES was presented to the chief of staff and chiefs of
service, and the decision to implement the system was ob-
tained. From September through December 2011, the la-
boratory procedure was written, the initial rules were
developed in consultation with the clinical chiefs of service,
and training was implemented for all involved participants.
The LES allowed for unit-specific exclusion from the util-
ization management rule sets. In general, patient test re-
quests that originated from critical care units and the
emergency department were automatically excluded.
On January 1, 2012, the system went live with initial
rules developed for 23 tests. During the first 4 days, the la-
boratory had additional staff present to handle questions, al-
though this proved to be unnecessary. The laboratory
monitored test volumes, cost savings, exclusions by clinician,
and other test utilization patterns to detect workaround ef-
forts. The laboratory continued to meet with the chief of staff
and chiefs of services on a monthly basis to review these
data, establish new test ordering rules, or edit existing rules.
When needed for specific tests, physicians from relevant sub-
specialties were consulted to establish appropriate frequency
filters. Attempts by clinicians to work around the LES, such
as an increase in ordering of renal panels, were dealt with by
incorporating the renal panel into the LES rule set. From
2012 through 2014, the rules were expanded to include up to
125 different tests (Supplemental Table 1; all supplemental
materials can be found at American Journal of Clinical
Pathology online).
Cost Savings Calculations
The Indianapolis VA system provides laboratory ser-
vices under a contractual agreement with equipment manu-
facturers using a basic cost per reportable for each
laboratory test performed. Cost per reportable includes re-
agents, calibrators, control material, disposables, training,
and a standard service agreement. For calculated cost sav-
ings, we only included laboratory cost savings using this
cost-per-reportable value. Cost savings were calculated by
determining the change in individual test volume relative to
the test volume in 2011, the last year testing was done be-
fore implementation of the LES. However, these calculated
cost savings assumed that test volumes would remain static
after 2011. Projected cost savings for each test were also
calculated using a best-fit regression line plotted against the
yearly pre-LES test volume. Using this best-fit regression
line, we then calculated the number of tests that would have
been performed in the years following LES implementation.
Projected savings thus take into account the projected in-
crease in test volume that did not materialize due to imple-
mentation of the LES.
Results
Continued Feedback Resulted in Reductions in
Exclusion Requests for Individual Patients
After triggering an LES rule for a test ordered on a spe-
cific patient, clinicians were allowed to contact the labora-
tory to request an exclusion for that patient. These
exclusions were always granted. However, clinicians were
tracked for the number of requested exclusions. This infor-
mation was passed on to the clinician’s service chief to
allow for feedback on test ordering practice if necessary.
Clinicians were initially allowed to ask for patient excep-
tions for an individual patient, which were granted for up to
7 days. This was then reduced to 3 days and finally to a sin-
gle occurrence in 2014. This approach led to a decrease in
the total numbers of exclusions requested as well as a de-
crease in the total numbers of clinicians with relatively large
numbers of exclusion requests within a given year Table 1 .
In addition, the experience of our teaching facility was that
most requests for multiday exceptions were initiated by resi-
dent physicians (Table 1).
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Implementation of the LES Resulted in a Significant
Reduction in Testing Volume
In Figure 1A , we show the test utilization trends for
total laboratory tests performed at the Indianapolis VA facil-
ity for calendar years 2004 to 2014. The number of compre-
hensive metabolic panels (CMPs), basic metabolic panels
(BMPs), and CBCs were also assessed in the years leading up
to the LES implementation in January 2012 and thereafter.
Total testing from 2004 to 2011 had a statistically significant
upward slope, as did pre-LES testing for CMP, BMP, and
CBC testing. In contrast, the number of total tests performed
as well as testing for all three common panel testing showed
a reversal of the ordering trend line post-LES. In contrast, 10
high-volume tests that were not subject to LES frequency fil-
ter rules continued to show year-to-year (YTY) increases in
test volume over the same time frame Figure 1B .
The above data strongly suggest that the LES system
worked as intended and played a key role in suppressing un-
needed testing. However, an alternative explanation for the
observed changes in laboratory test frequency would be that
these changes represented reductions in outpatient or inpa-
tient census numbers. In Figure 1C , we show that there
was no significant difference in the YTY change in outpa-
tient visits when assessed before and after implementation
of the LES (mean YTY change ¼ 6.57% pre-LES relative to
a 6.08% post-LES). Moreover, there was no change in bed
days of care in the 2 years before implementing the LES
relative to the first 2 years after implementing the LES
Figure 1D . Thus, there is no evidence that changes in
outpatient visits or inpatient occupancy rates were respon-
sible for the post-LES decline in test ordering.
To verify that the testing volumes for both total tests
and high-volume panel testing were significantly different
between the pre- and post-LES periods of time, we plotted
the mean YTY change in testing volumes for 5 to 8 years
leading up to the LES implementation and the 3 years fol-
lowing Figure 2 . Total testing volumes rose at a mean of
8.76% year to year before LES implementation but fell to a
5.68% YTY decrease after LES implementation Figure 2A.
Likewise, similar YTY increases in testing volumes were
noted for CBCs (Figure 2B: 9.30% mean YTY increase),
CMPs (Figure 2C: 10.94% mean YTY increase), and BMPs
(Figure 2D: 5.52% mean YTY increase) before implement-
ing the LES. This was followed by a YTY reduction in post-
LES testing volumes for all three high-volume test panels (–
5.33%, –1.00%, and –12.75% mean YTY reductions for
CBCs, CMPs, and BMPs, respectively).
Implementation of the LES Has No Measureable Effect
on Inpatient Length of Stay
The LES rules that were developed for panel testing
(CBC, CMP, and BMP) were designed to prevent repeated
panel testing within a 24-hour period. Since repeat panel
testing within the same day would be highly unusual for out-
patient testing, the ability of these rules to reduce test panel
utilization would be expected to be limited to inpatient la-
boratory testing. Since it is possible that overly vigorous
cost containment measures could negatively affect patient
care by preventing early recognition of a patient’s change in
health or treatment status, we also sought to assess whether
the implementation of the LES altered the average length of
stay for inpatients. We show there is no significant differ-
ence in the average length of stay Figure 3 in the years fol-
lowing LES implementation. The laboratory also monitored
incoming incident reports to determine whether any inci-
dents could be directly tied to the implementation of the
LES. There have been no incident reports received by the la-
boratory that would indicate that the LES resulted in a delay
in diagnosis or treatment or resulted in any potential or ac-
tual patient harm.
Continued Revisions and Expansion of Rules Allowed
for a Continued Decrease in Total Test Volume
Following implementation of a test frequency filter, it
might be expected that the major decrease in test volume
would be realized in the first year of implementing this
type of utilization management tool. Thereafter, it might
be expected that testing would revert to the previous YTY
change in test order frequency. As seen in (Figure 1A),
ordering for CMPs showed a pattern consistent with this
idea. However, this pattern was not seen for total tests,
CBCs, and BMPs. In these cases, we saw a continued re-
duction in test volumes through the first 3 years of LES im-
plementation. This was particularly dramatic for total tests
Table 2 . Total tests, relative to calendar year 2011, were
reduced by 5.07% in the first year, followed by more dra-
matic decreases of 12.37% and 16.11% in years 2 and 3
following implementation of the LES. However, it should
also be noted that actual reductions in total laboratory test-
ing relative to pre-LES numbers are somewhat misleading
(Table 2). As shown in (Figures 1A and 2A), total testing
volumes showed a consistent YTY increase before imple-
mentation of the LES. Thus, assuming that total test
Table 1
Exclusion Requests by Providers for Individual Patients
Year
No. of Exclusions
Granted
No. of Clinicians
With 10
Exclusions
% of Clinicians With
10 Exclusions
Resident Staff
2012 6,532 158 78 22
2013 4,058 103 62 38
2014 3,769 80 91 9
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volumes would have increased at the 8.76% YTY rate
observed before LES implementation, then our projected
decrease in total test volumes would have been signifi-
cantly higher (a mean of –19.80% YTY over the 3 years of
the program relative to the mean –11.18% YTY reduction
seen when reductions are assumed to be relative to a static
baseline based on calendar year 2011 data).
Calculated Cost Savings
In Table 3 , we show the calculated cost savings rela-
tive to 2011 that were realized by reductions in three high-
volume panel tests (CBC, BMP, and CMP). These large
panel tests were included because they are high-volume
tests. Moreover, these test panels are highly unlikely to trig-
ger test frequency filters for outpatient visits. Thus, the
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Figure 1 The laboratory expert system (LES) laboratory utilization management approach reverses a trend toward increasing
total tests and specific high-volume panel testing over time that is not due to changes in outpatient visits or inpatient volume.
A, The total number of laboratory tests (total tests), as well as the number of basic metabolic panels (BMPs), comprehensive
metabolic panels (CMPs), and CBCs, performed by the Richard L. Roudebush VA Medical Center Clinical Laboratory is plotted
per calendar year. The LES was implemented on January 1, 2012. Thus, pre-LES testing is plotted up until and including calen-
dar year 2011. Post-LES testing included years 2012 to 2014. For the pre-LES years, the slope of the best-fit regression line for
all tests was positive and significantly different from zero (no change in test volume: P ¼ .0001 [total tests]; P ¼ .0011 [CBC]; P
< .0001 [CMP and BMP]). In contrast, the slope of the best-fit lines post-LES was negative and statistically different from the
pre-LES best-fit lines for all tests: P ¼ .0012 (total tests), P ¼ .00038 (CBC), P ¼ .00012 (BMP), and P ¼ .0012 (CMP). B, The
sum of total testing from 10 different high-volume tests not subject to LES rules is plotted for each calendar year from 2011 to
2014. The 10 tests included in this assessment were a-fetal protein, carcinoembryonic antigen, C-reactive protein, ethanol, fer-
ritin, iron, ammonia, salicylate, total iron binding capacity, and valproic acid. C, The mean6 SD number of outpatient visits per
year is plotted for the 5 years preceding the LES system implementation and the 2 years of complete data post-LES implemen-
tation. No significant difference was observed.D, The mean 6 SD number of inpatient bed days of care for the 3 years leading
up to LES implementation and the 2 years following LES implementation is shown. No significant difference was observed.
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changes in these high-volume test panels reflect the cost
containment changes that might be expected for inpatient
testing under existing diagnosis-related group (DRG) reim-
bursement schemes. Actual tests per year represent the
actual number of tests performed in the given calendar year.
The projected test numbers were obtained by fitting a re-
gression line to the test volumes for each specific test panel
before LES implementation. This linear equation was then
used to project what test volumes for each test panel would
have been for years 2012 through 2014.
Using actual test numbers, we calculated cost savings
due to actual test numbers relative to the test numbers ob-
tained in calendar year 2011, the last year testing was done
without LES implementation. This was calculated from the
contractually negotiated cost per reportable for each panel
(CBC ¼ $1.75, CMP ¼ $2.58, and BMP ¼ $1.32).
However, this number likely underestimates the true cost
savings, since test volumes for all three panel tests had been
increasing at a YTY rate of 5.52% to 10.94% (see Figure 2).
Thus, using projected test volumes for calendar years 2012
to 2014, we estimated the cost savings that would have
been realized if the projected increase in test volumes had
occurred. This difference between projected and actual sav-
ings was dramatic. Using actual test volume numbers, the
laboratory saved a cumulative amount of $206,214 over the
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Figure 2 The effect of laboratory expert system (LES) implementation on mean year-to-year (YTY) change in total tests and
high-volume panel testing. The YTY percent change in testing volumes was calculated for 6 to 8 years before implementation
of the LES time period. The YTY change in testing was then calculated for the 3-year period following implementation of the
LES. A, Mean YTY increase in total test volumes (8.76%) relative to a mean –5.68% reduction in YTY in total tests following
LES implementation. B, CBC testing volumes rose at a 9.3% YTY mean increase before LES implementation compared with a
–5.33% mean decrease from 2011 to 2014. C, Comprehensive metabolic panel (CMP) testing had a 10.94%mean increase
per year over 2004 to 2011 but had a –1.0% mean decrease in testing volume per year after 2011. D, Basic metabolic panel
(BMP) testing volumes changed from a 5.52% mean increase YTY relative to a –12.75% decrease YTY after implementation of
the LES. All data are shown as the mean 6 SD.
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Figure 3 Implementation of laboratory utilization manage-
ment had no significant effect on inpatient mean length of stay.
For 2002 to 2014, we obtained the mean days of stay for each
calendar year. For the 10 years leading up to laboratory expert
system implementation (2002-2011), the mean length of stay
was 5.016 0.041 (mean6 SD) days. For 2012 to 2014, the
mean length of stay was 5.006 0.1 days (P¼ .9142).
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2012 to 2014 period due to reduced cost per reportables for
these three high-volume panel tests. However, taking into
account the trend for increasing orders for panel testing,
cost savings were likely much higher (the estimated pro-
jected total savings from for the 3-year period following the
LES implementation for these three commonly ordered test
panels was $469,162).
Finally, we calculated total cost savings realized in
each year due to reductions in testing volumes for all tests
included in the LES. Relative to the test volumes observed
in calendar year 2011 and assuming static total test volumes
thereafter, the laboratory savings were calculated to be
$151,814 for calendar year 2012 and $163,751 for calendar
year 2013 (Supplemental Table 2). This corresponded to a
yearly average reduction of our total test volume of approxi-
mately 11.3% per year (Table 2). Projecting cost savings
due to historic YTY volume changes was not practical, since
many of the tests are lower volume tests that exhibit higher
YTY variances. However, as mentioned above, projected
total test volumes were reduced by a mean of 19.8% YTY.
Thus, it could be concluded that our true cost savings may
have been approximately 75% higher than our calculated
cost savings.
Discussion
In an attempt to safely reduce laboratory costs through
the suppression of redundant or unnecessary testing, we re-
port the implementation of a laboratory test utilization man-
agement system (LES) that assigned test frequency filters for
commonly used laboratory tests and test panels. This system
was designed to work at the point of test order through the
VA VistA CPOE system. While no test was absolutely
denied, the LES offered a significant roadblock to repetitive
ordering: ordering clinicians were required to contact the la-
boratory to have a frequency filter lifted for a given patient.
The gains realized through the implementation included
a substantial cost savings for the clinical laboratory. Test re-
ductions from all LES listed tests (Supplemental Table 1)
Table 2
Reduction in Total Tests Relative to 2011 and to Projected Increases
Calendar Year
Actual
No. of TT/y
Projected
No. of TT/y
% Reduction
(TT/y) (Relative to 2011)
% Reduction Based
on Projected Increase
2011 2,762,263 NA NA NA
2012 2,622,113 2,909,759 –5.07 –9.89
2013 2,420,469 3,071,404 –12.37 –21.19
2014 2,317,258 3,233,048 –16.11 –28.33
Mean (2012-2014) –11.18 –19.80
NA, not available; TT, total tests.
Table 3
Actual and Projected Cost Savings for Selected Panel Tests
Calendar Year
Actual
No. per Year
Projected
No. per Year
Savings
(Relative to 2011), US$
Savings Based on Projected
Increase, US$
CBC
2011 120,980 NA NA NA
2012 109,093 132,815 20,802 41,514
2013 107,302 141,258 23,937 59,423
2014 102,447 149,701 32,433 82,694
Total: 2012-2014 318,842 423,774 77,172 183,631
BMP
2011 68,474 NA NA NA
2012 51,565 74,737 22,320 30,586
2013 47,724 78,213 27,390 40,246
2014 44,808 81,690 31,239 48,684
Total: 2012-2014 144,097 234,640 80,949 119,516
CMP
2011 78,518 NA NA NA
2012 71,687 87,917 17,624 41,872
2013 69,633 93,753 22,923 62,231
2014 75,593 99,590 7,547 61,913
Total: 2012-2014 216,913 281,260 48,094 166,016
BMP, basic metabolic panel; CMP, comprehensive metabolic panel; NA, not available.
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resulted in an estimated $151,814 in savings during the first
year of implementation and $163,751 in the second year
(2.02% and 2.18% reductions in the total laboratory budget).
This cost reduction was based on savings related to testing
volume reductions from calendar year 2011, the last year in
which the LES system was not used. Given that total labora-
tory tests had experienced a mean increase in test volume of
8.76% per year in the 8 years before implementing the LES,
this savings estimate is likely considerably lower than the
true reduction in laboratory costs. Considerable cost savings
came from the reduction in testing using high-volume large
panel testing (CBCs, CMPs, and BMPs). Additional signifi-
cant cost savings came from applying test frequency filters
for lower volume but high-cost tests (eg, hepatitis C virus
viral load).
The continued YTY reduction in total tests and in spe-
cific test panels that we observed over a 3-year period was
likely due to a number of factors. First, following imple-
mentation of the LES, there was an ongoing review of the
data resulting in a number of refinements. Refinements
included ongoing training for the ordering physicians by the
chiefs of service, minor alterations in our test frequency fil-
ters, and reducing the ability of clinicians to exclude indi-
vidual patients for multiple days. Reductions in total test
volumes in the second and third years are also attributable
to our expansion of the number of tests in which we insti-
tuted test frequency filters. It is expected that as we exhaust
possible tests that can be incorporated into the LES, we will
lose our ability to see continued reductions in test volumes
and cost savings.
While volume reductions were noted for CBC, BMP,
and CMP panel testing, this reduction was less marked for
CMP testing. There are several possible explanations for this
observation. First, as we have noted, outpatient testing would
be infrequently associated with repeat testing that would trig-
ger the frequency filter rule. In our experience, CMP testing
is more frequently ordered on outpatients at our VA facility
than CBCs or BMPs. Thus, there would be a smaller subset
of inpatient CMP ordering that would be likely to trigger
LES frequency filters. Second, CMPs provide more informa-
tion than BMP testing, and thus CMPs may be ordered more
frequently in metabolically unstable patient populations
within the critical care units or emergency departments that
were automatically excluded from the LES frequency filters.
Third, the CMP testing may represent a workaround when
BMP or renal panel testing is blocked.
Electronic laboratory utilization management approaches
have been used with some success to limit redundant testing in
US hospitals. In general, most published approaches have
involved noninterventional alerts or alerts that require some ac-
tion by the ordering physician at the level of the CPOE (eg,
closing a pop-up alert) (reviewed in Baron and Dighe12).
Systems that block order entry through the CPOE and require
manual override at the level of the laboratory information sys-
tem have also been described.10,14,15 These have been limited
systems that involve a relatively small number of analytes or
high-cost send-out tesing.10,14,15 One unique aspect of our util-
ization management approach was to initially target high-
volume, low-cost test panels (eg, BMP, CMP, and CBC).
Large test panels are very convenient for assessing a patient’s
global metabolic, physiologic, or hemodynamic status.
However, these panels are very frequently overused in the in-
patient setting.6,7,14 The high rate of false positives associated
with the ordering of a large panel of tests can also lead to un-
necessary diagnostic testing, particularly by less experienced
or risk-averse clinicians. This is particularly true if clinicians
order a repeat panel to investigate an abnormal result for a
small subset of analytes. Thus, while these panels are relatively
inexpensive for the laboratory to run, we were able to obtain a
significant cost savings by introducing frequency filters for
large panel tests.
The drawback to such an approach is the interruption in
clinicians’ work flow, as well as the possibility of a delay in
testing for a patient whose clinical status had changed rap-
idly. We therefore assessed not only cost reductions but also
a critical measure of patient safety. There was no change in
patient length of stay following the implementation of the
LES. Moreover, the laboratory did not receive any incident
reports indicating that the system resulted in patient harm.
Finally, there were surprisingly few complaints from clin-
icians regarding the implementation of the system. This
likely reflects the buy-in and active involvement of the vari-
ous service chiefs.
In assessing cost savings accrued through the use of the
LES, it should be noted that we only accounted for the cost
savings from not performing the specific test on our analyt-
ical instruments (cost per reportable). We did not include
cost reductions due to preanalytical variables (phlebotomy
time savings, reduced test tube and needle utilization) or
factor in savings due to reduced laboratory staff workload
for analytical testing or for postanalytical verifications and
reporting. In our study, total tests were reduced a mean of
11.27% per year relative to 2011 levels in the 3 years the
LES has been in place. Thus, this reduction in testing would
have resulted in reduced laboratory staff workloads.
However, reductions in laboratory workloads were offset
for the time needed for clinical staff to call in exclusions
and for laboratory staff to execute exclusions. Nor did we
factor in the time needed by both laboratory and clinical
management teams to implement, evaluate, and refine the
LES. However, laboratory utilization management at one fa-
cility produced considerable labor savings from reductions
in phlebotomy services.15 In this report, a similar frequency
filter to limit unnecessary testing of five high-volume and
Konger et al / ELECTRONIC LAB UTILIZATION MANAGEMENT
362 Am J Clin Pathol 2016;145:355-364 © American Society for Clinical Pathology
362 DOI: 10.1093/ajcp/aqv092
overused tests was implemented at San Francisco General
Hospital, a municipal teaching facility. They observed
41,765 fewer inpatient tests (6.9% reduction) that were dir-
ectly attributable to the frequency filters in the first year
after implementing this system. Importantly, this resulted in
17,207 (21.4%) fewer inpatient phlebotomies. Given that
we saw a greater reduction in total test volumes (mean
11.27% reduction YTY), it is likely that there were consid-
erable labor savings due to reduced phlebotomy services by
the phlebotomy and nursing staff that we have not factored
into the cost reduction analysis.
Redundant laboratory testing has been estimated to re-
sult in $5 billion in unnecessary laboratory costs annu-
ally.9,12 Certainly, reductions in unnecessary laboratory
testing are a financially sound approach for government-run
hospitals. In contrast, for nongovernment US hospital sys-
tems, the clinical laboratories currently serve as revenue
centers for outpatient testing. Thus, there is little financial
incentive for initiating laboratory test utilization manage-
ment controls for outpatient testing.16 However, DRG reim-
bursement schemes result in clinical laboratories serving as
cost centers for inpatient testing. Thus, there is a financial
incentive for hospitals to reduce inpatient laboratory testing
costs.7,16-18 While it is difficult to extrapolate our cost sav-
ings to estimate the potential cost savings nationwide, a
rough estimate could be calculated by our cost savings per
patient days of care. For just high-volume panel testing
(CBC, CMP, and BMP) that would largely affect inpatient
testing costs, this cost savings averaged $1.17 per patient
day of care if testing volumes were assumed to remain static
at 2011 levels. If projected testing volume increases were
factored in, the cost savings would have averaged $2.67 per
patient day of care. In 2005, a total of 4,936 US community
hospitals treated 39.2 million patients over 181.5 million
days of care.19 Thus, using our estimated actual or projected
cost savings per inpatient day of care just for these three
panel tests, a reduction of $212.4 to $484.6 million in na-
tionwide laboratory direct testing costs could potentially be
realized in the first year of implementing a similar system in
US health care facilities. A number of other factors could
also reduce or increase this estimate. Certainly, laboratory
costs vary considerably depending on the specific DRG.18
Thus, this estimate would fail to take into account differ-
ences in the mix of inpatient DRGs relative to other facili-
ties. Additional cost savings would be likely from reduction
in preanalytical testing costs and labor costs (eg, blood
draws). However, it is also likely that diminishing cost sav-
ings would accrue after the first 3 to 4 years of implement-
ing the system as clinicians incorporate the new ordering
guidelines into their clinical practice.
Recently, the US Department of Health and Human
Services has announced plans to speed up the introduction
of value-based reimbursement schemes for all Medicare ser-
vices.20 Thus, it is likely that outpatient testing on a fee-for-
service basis will eventually be phased out. This would have
profound implications on laboratory utilization since it
would force the conversion of hospital clinical laboratories
from revenue centers to primarily cost centers. In this event,
cost savings from the reduction of unnecessary or duplica-
tive diagnostic testing will become a priority.
From a utilization management perspective, it should not
be overlooked that the Richard L. Roudebush VA Medical
Center is a teaching hospital. Redundant testing has been re-
ported to be greater in teaching hospitals where inpatient la-
boratory tests are ordered by resident physicians.15 Indeed, we
have found that most clinicians’ requesting exclusions were
from resident physicians. Experienced physicians infrequently
requested exclusions. After review by chiefs of service, re-
quests for multiday exclusions for individual patients were
found to be unnecessary. This resulted in the LES committee
gradually reducing the ability to ask for an exclusion for a
given patient from a maximum of 7 days to 3 days and finally
to a single onetime exclusion. Thus, for nonteaching hospitals
staffed largely with experienced clinicians, it is possible that a
simple noninterruptive alert providing the physicians with the
most recent laboratory data would suffice to prevent redundant
orders. For training facilities such as ours, a more rigorous ap-
proach requiring active involvement of the laboratory may
prove more useful.
It is important to note that the ability to implement the
LES at the Indianapolis VA Medical Center is dependent on
the VistA system used by all VA facilities. Thus, one con-
siderable roadblock to implementation of a robust utiliza-
tion management system is the necessity for a CPOE. While
there has been considerable pressure on US health care
facilities to adopt CPOE due to the Health Information
Technology for Economic and Clinical Health Act of 2009,
the independent research firm KLAS has estimated that
only 21.7% of nonfederal US hospitals had fully adopted
CPOE by 2011.21 Certainly, additional hospitals have
acquired CPOE since 2011, as hospitals adopting basic elec-
tronic health record systems have gone from 27.6% in 2011
to 59.4% in 2013.22 Thus, it might be expected that a similar
relative increase in CPOE adoption may have occurred.
Nonetheless, adoption of CPOE is lagging due to several po-
tential issues, not the least of which is the considerable cost
to a hospital to adopt a CPOE system.13 Thus, incorporating
a laboratory utilization management system to reduce
costs due to inpatient testing could be factored into the cost-
benefit analysis for switching to CPOE systems.
Finally, the successful implementation of a test fre-
quency filter for laboratory test utilization management is
very heavily dependent on a strong working relationship be-
tween the laboratory, information systems specialists,
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hospital administration, and clinicians. Monthly meetings
allowed for continued monitoring for efficacy as well as re-
finements to the frequency filters. This peer-based approach
allowed for better acceptance from the clinical staff.
Moreover, the early involvement of resident physicians in the
initial training period and involvement of the clinical staff in
providing appropriate feedback to the residents proved to be
a crucial element to successful implementation.
Corresponding author: Raymond Konger, 975 West Walnut St,
IB424F, Indianapolis, IN 46202; rkonger@iupui.edu.
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